AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

The North Chicago-based company announced today it entered into an option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and immune diseases. Neomorph ...

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive ...

(RTTNews) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...